Interview with Deepak L. Bhatt, MD, MPH
How has Cardiovascular Intervention, 2nd Edition evolved since the previous edition?
This is the second edition. Since the first edition, there have been important advances in interventional cardiology. The approaches to left main bifurcations and chronic total occlusions are completely different compared with the first edition. Interventions in structural heart disease have evolved at a rapid pace, particularly with respect to transcatheter aortic valve replacement, as well as with transcatheter mitral and tricuspid valve interventions.
What is the most exciting aspect of the new edition? What chapter or topic covered in the new edition are you most excited about?
There are several new figures, tables, and videos of the latest advances in interventional cardiology. In particular, structural heart disease has come a long way.
Who will find the greatest value from Cardiovascular Intervention, 2nd Edition and why? Has the audience changed since the book was first published?
Interventional cardiologists, cardiac and vascular surgeons, interventional radiologists and neurologists, trainees, medical students, nurses and nurse practitioners, physician assistants, industry partners, researchers, and others involved with patients undergoing cardiovascular interventions.
What problem do you hope the future generation of your specialty will be able to solve?
Hopefully, the techniques described in this book will help usher in the next stage in the evolution of interventional cardiology.
About the Editor
Deepak L. Bhatt MD, MPH, FACC, FAHA, FESC, MSCAI, is Director of Mount Sinai Heart and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai Health System.
After graduating as valedictorian from Boston Latin School, Dr. Bhatt obtained his science degree as a National Merit Scholar at MIT. He received his MD from Cornell and MPH from Harvard. He is working on his Executive MBA from Oxford. He trained in internal medicine at the University of Pennsylvania and in cardiology at Cleveland Clinic. He completed fellowships in interventional cardiology and cerebral and peripheral vascular intervention and served as Chief Interventional Fellow at Cleveland Clinic, where he spent many years as an interventional cardiologist, Associate Professor of Medicine, Director of the Interventional Cardiology Fellowship, Associate Director of the Cardiovascular Medicine Fellowship, and Associate Director of the Cardiovascular Coordinating Center. He then served as the Chief of Cardiology at VA Boston Healthcare System and subsequently as Executive Director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital. He was a Senior Investigator in the TIMI Study Group and Editor-in-Chief of the Harvard Heart Letter. He became a full Professor of Medicine at Harvard Medical School in 2012. He was selected by Brigham and Women’s Hospital as the 2014 Eugene Braunwald Scholar. He received the Research Mentor Award from Brigham and Women’s Hospital Department of Medicine in 2016, the Eugene Braunwald Teaching Award for Excellence in the Teaching of Clinical Cardiology from Brigham and Women’s Hospital in 2017, ACC’s Distinguished Mentor Award in 2018, AHA’s Distinguished Scientist Award in 2019, NLA’s Honorary Lifetime Membership Award in 2021, and SCAI’s Master designation in 2022.
Dr. Bhatt has authored or co-authored over 2000 publications and has been listed by the Web of Science Group as a Highly Cited Researcher from 2014 to 2022. He is the Editor of Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease and of Opie’s Cardiovascular Drugs: A Companion to Braunwald’s Heart Disease. He is one of the co-Editors of Braunwald’s Heart Disease. He had served as Senior Associate Editor for News and Clinical Trials for ACC.org and is the Editor of the Journal of Invasive Cardiology. He was the PI for CHARISMA, CRESCENDO, COGENT, REDUCE-IT, SOLOIST, SCORED, and ENTRIGUE and co-PI of the three CHAMPION trials, STAMPEDE, SAVOR-TIMI 53, SYMPLICITY HTN-3, THEMIS, THEMIS-PCI, and the REACH registry. In 2014, he was listed in the AHA/ASA top advances in heart disease and stroke research (for STAMPEDE and SYMPLICITY HTN-3); in 2018, REDUCE-IT was listed and also named the top cardiology trial by NEJM; in 2020 and again in 2021, SOLOIST and SCORED were listed by the AHA. He was the inaugural Chair of the AHA-GWTG Quality Oversight Committee and served as a Trustee of the ACC, and currently serves on the Board of Directors of the AHA New York City chapter.
Purchase your copy of Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease, 2nd Edition here!